Lucid Diagnostics (LUCD) Cash from Investing Activities Growth (1y) (2022 - 2026)
Lucid Diagnostics (LUCD) Cash from Investing Activities Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -4,224.26% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 95.53% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 3.20% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -18.20% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -208.79% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | -187.82% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | -397.90% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | -514.25% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | -211.17% |
| 10 | Lucid Diagnostics | 149.20 Mn | 121.33 Mn | -325,000.00 | -131.18% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -131.18% |
| Dec 31, 2025 | 80.31% |
| Sep 30, 2025 | 92.00% |
| Mar 31, 2025 | -151.35% |
| Dec 31, 2024 | -48.00% |
| Sep 30, 2024 | -2,400.00% |
| Mar 31, 2024 | -117.65% |
| Dec 31, 2023 | 13.79% |
| Sep 30, 2023 | 98.94% |
| Jun 30, 2023 | 99.38% |
| Mar 31, 2023 | 88.51% |
| Dec 31, 2022 | 75.36% |
| Sep 30, 2022 | -4,617.86% |
| Jun 30, 2022 | -243,500.00% |
| Mar 31, 2022 | -1,544.44% |